Trade BCTXL stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) is trading at US$0.89, down 1.36% today as of Oct 15, 16:00 EDT. Over the past 52 weeks, BCTXL has traded between US$0.61 and US$1.40. On Syfe you can trade BCTXL with $0 commission and add it to your watchlist.
| Previous close | US$0.90 |
|---|---|
| 52-week range | US$0.61 – US$1.40 |
| Volume | 38.24K |
| Exchange | US |
BriaCell Therapeutics Corp. Warrant expiring 2031
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
Year: 2026
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) stock is trading at US$0.89, -1.36% from the previous close of US$0.90.
The 52-week high for BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) stock is US$1.40.
The 52-week low for BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) stock is US$0.61.
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) does not currently pay a dividend.
Stay on top of BCTXL
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
